SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Chin-Lin Huang, I-Lun Hsiao, Ho-Chen Lin, Chu-Fang Wang, Yuh-Jeen Huang, Chun-Yu Chuang, Silver nanoparticles affect on gene expression of inflammatory and neurodegenerative responses in mouse brain neural cells, Environmental Research, 2015, 136, 253

    CrossRef

  2. 2
    Antoine Leuzy, Eduardo Rigon Zimmer, Serge Gauthier, Pedro Rosa-Neto, Amyloid imaging in Alzheimer’s disease: a potential new era of personalized medicine?, Translational Neuroscience, 2014, 5, 1, 51

    CrossRef

  3. 3
    Alberto Lleó, Enrica Cavedo, Lucilla Parnetti, Hugo Vanderstichele, Sanna Kaisa Herukka, Niels Andreasen, Roberta Ghidoni, Piotr Lewczuk, Andreas Jeromin, Bengt Winblad, Magda Tsolaki, Barbara Mroczko, Pieter Jelle Visser, Isabel Santana, Per Svenningsson, Kaj Blennow, Dag Aarsland, José Luis Molinuevo, Henrik Zetterberg, Brit Mollenhauer, Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases, Nature Reviews Neurology, 2014,

    CrossRef

  4. 4
    Kaj Blennow, Bruno Dubois, Anne M. Fagan, Piotr Lewczuk, Mony J. de Leon, Harald Hampel, Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease, Alzheimer's & Dementia, 2014,

    CrossRef

  5. 5
    Niklas Mattsson, Philip S. Insel, Susan Landau, William Jagust, Michael Donohue, Leslie M. Shaw, John Q. Trojanowski, Henrik Zetterberg, Kaj Blennow, Michael Weiner, Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease, Annals of Clinical and Translational Neurology, 2014, 1, 8
  6. 6
    Flora H. Duits, Niels D. Prins, Afina W. Lemstra, Yolande A.L. Pijnenburg, Femke H. Bouwman, Charlotte E. Teunissen, Philip Scheltens, Wiesje M. van der Flier, Diagnostic impact of CSF biomarkers for Alzheimer's disease in a tertiary memory clinic, Alzheimer's & Dementia, 2014,

    CrossRef

  7. 7
    David M Cash, Jonathan D Rohrer, Natalie S Ryan, Sebastien Ourselin, Nick C Fox, Imaging endpoints for clinical trials in Alzheimer’s disease, Alzheimer's Research & Therapy, 2014, 6, 9

    CrossRef

  8. 8
    Stephen N. Gomperts, Imaging the Role of Amyloid in PD Dementia and Dementia with Lewy Bodies, Current Neurology and Neuroscience Reports, 2014, 14, 8

    CrossRef

  9. 9
    Panagiotis Alexopoulos, Laura Kriett, Bernhard Haller, Elisabeth Klupp, Katherine Gray, Timo Grimmer, Nikolaos Laskaris, Stefan Förster, Robert Perneczky, Alexander Kurz, Alexander Drzezga, Andreas Fellgiebel, Igor Yakushev, Limited agreement between biomarkers of neuronal injury at different stages of Alzheimer's disease, Alzheimer's & Dementia, 2014, 10, 6, 684

    CrossRef

  10. 10
    Jon B Toledo, Michael W Weiner, David A Wolk, Xiao Da, Kewei Chen, Steven E Arnold, William Jagust, Clifford Jack, Eric M Reiman, Christos Davatzikos, Leslie M Shaw, John Q Trojanowski, Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition, Acta Neuropathologica Communications, 2014, 2, 1, 26

    CrossRef

  11. 11
    Josef Pannee, Ulrika Törnqvist, Anni Westerlund, Martin Ingelsson, Lars Lannfelt, Gunnar Brinkmalm, Rita Persson, Johan Gobom, Johan Svensson, Per Johansson, Henrik Zetterberg, Kaj Blennow, Erik Portelius, The amyloid-β degradation pattern in plasma—A possible tool for clinical trials in Alzheimer's disease, Neuroscience Letters, 2014, 573, 7

    CrossRef

  12. 12
    José Luis Molinuevo, Kaj Blennow, Bruno Dubois, Sebastiaan Engelborghs, Piotr Lewczuk, Armand Perret-Liaudet, Charlotte E. Teunissen, Lucilla Parnetti, The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative, Alzheimer's & Dementia, 2014, 10, 6, 808

    CrossRef

  13. 13
    Martina Bocchetta, Samantha Galluzzi, Patrick Gavin Kehoe, Eduardo Aguera, Roberto Bernabei, Roger Bullock, Mathieu Ceccaldi, Jean-François Dartigues, Alexandre de Mendonça, Mira Didic, Maria Eriksdotter, Olivier Félician, Lutz Frölich, Hermann-Josef Gertz, Merja Hallikainen, Steen G. Hasselbalch, Lucrezia Hausner, Isabell Heuser, Frank Jessen, Roy W. Jones, Alexander Kurz, Brian Lawlor, Alberto Lleo, Pablo Martinez-Lage, Patrizia Mecocci, Shima Mehrabian, Andreas Monsch, Flavio Nobili, Agneta Nordberg, Marcel Olde Rikkert, Jean-Marc Orgogozo, Florence Pasquier, Oliver Peters, Eric Salmon, Carmen Sánchez-Castellano, Isabel Santana, Marie Sarazin, Latchezar Traykov, Magda Tsolaki, Pieter Jelle Visser, Åsa K. Wallin, Gordon Wilcock, David Wilkinson, Henrike Wolf, Görsev Yener, Dina Zekry, Giovanni B. Frisoni, The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey, Alzheimer's & Dementia, 2014,

    CrossRef

  14. 14
    Jon B. Toledo, Sharon X. Xie, John Q. Trojanowski, Leslie M. Shaw, Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI, Acta Neuropathologica, 2013, 126, 5, 659

    CrossRef

  15. 15
    Meredith N. Braskie, Paul M. Thompson, Understanding cognitive deficits in Alzheimer's disease based on neuroimaging findings, Trends in Cognitive Sciences, 2013, 17, 10, 510

    CrossRef